About Telik
Telik is a publicly listed company based in Palo Alto (United States) founded in 1988. Small molecule drugs for cancer treatment are discovered and developed. Its chief executive, as recorded, is David Hansen. Its focus areas include Life Sciences, Oncology, Drugs and Diversified. Its competitors include C4 Therapeutics, Erasca and Revolution Medicines; 3 of its 3 listed competitors have raised funding.
Company details
Telik was founded in 1988 in Palo Alto, United States, as a clinical-stage biotechnology firm. Small molecule drugs targeting cancer are discovered and developed using the proprietary Target-Related Affinity Profiling (TRAP) platform, which relies on interactions between drugs and cellular proteins. The lead candidate, Telintra, a modified glutathione analog, was advanced for hematologic disorders such as myelodysplastic syndrome, though development was terminated. Operations center on oncology therapeutics.
- Headquarters Palo Alto, United States
- Stage Public
- SectorsHealthcare
- Website telik.com
- Latest Funding Round$5.19M (USD), Post-IPO
Jul 2014
- InvestorsGimv
& 1 more
Funding Insights of Telik
- Total Rounds 4
- Last Round Post-IPO — $5.19M
- Investors Count 2
All 4 funding rounds of Telik with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul 2014 | $5.19M | Post-IPO | – | – | – |
| May 2014 | $4.58M | Post-IPO | – | – | – |
| Jun 1995 | Unspecified | – | – | ||
| Nov 1994 | Unspecified | – | – |
2 investors in total: 2 institutional.
Investors in Telik
Telik has secured backing from 2 investors, including venture fund investors. Prominent investors backing the company include Gimv and Advent International.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Private equity firm | 1980 | gimv.com | Antwerp, Belgium | |
Private equity firm focused on multiple sectors | adventinternational.com | Sao Paulo, Brazil |
Investor details for Telik
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Telik
1 people are tracked at Telik (1 in leadership).
| Name | Role | Group |
|---|---|---|
David Hansen | CEO & President | Leadership |
Complete people profiles for Telik
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Telik
4 dated milestones of Telik across 26 years, from founding to its latest funding, stage changes and deals.
- Founded Telik is founded.
- Funding First funding round.
- IPO Lists on the stock exchange (IPO).
- Funding Latest funding round, Post-IPO, of $5.2M.
Competitors of Telik
Telik has 3 listed competitors in our database, 3 of them funded. They include C4 Therapeutics, Erasca and Revolution Medicines.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| c4therapeutics.com | 2016 | Cambridge, United States | $223M | 121 | Small-molecule drugs for cancer treatment are developed via Degronimid platform. | |
| erasca.com | 2018 | San Diego, United States | $300M | 120 | Small molecule therapeutics for cancer treatment are developed. | |
| revmed.com | 2014 | Redwood, United States | $326.29M | 181 | Cancer therapies are developed using selective pathway inhibitors. |
Detailed competitors of Telik
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Telik
Websites that share an audience with Telik (telik.com).
Websites whose visitors overlap most with Telik. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
finance.yahoo.com | finance.yahoo.com | 100% | #205 | – | |
| thresholdpharm.com | 98% | View details | |||
| tercica.com | 96% | View details | |||
| supergen.com | 69% | View details |
Top companies in Oncology
3 companies that operate in the same segment as Telik (Oncology) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Telik
Telik was founded in 1988 and raised its 1st funding round 6 years after it was founded.
Telik is headquartered in Palo Alto, United States. It is registered at Palo Alto, California, United States.
David Hansen is the CEO of Telik, as recorded in our data.
Telik was founded in 1988 in Palo Alto, United States, as a clinical-stage biotechnology firm. Small molecule drugs targeting cancer are discovered and developed using the proprietary Target-Related Affinity Profiling (TRAP) platform, which relies on interactions between drugs and cellular proteins. The lead candidate, Telintra, a modified glutathione analog, was advanced for hematologic disorders such as myelodysplastic syndrome, though development was terminated. Operations center on oncology therapeutics.
Telik's top competitors include C4 Therapeutics, Erasca and Revolution Medicines.
Telik has 2 investors. Key investors include Gimv, and Advent International.